The company’s Phase III clinical study of the nine-valent HPV vaccine is ongoing.
October 2, 2025
Source: drugdu
159
an investor asked on the investor interaction platform: When is the company's nine-valent vaccine expected to be launched? What is its current stage? What is the annual production capacity of the company's production line?
Watson Bio(300142.SZ) stated on the investor interaction platform on September 24 that the company's related work on the Phase III clinical study of the nine-valent HPV vaccine is ongoing. If there is any substantial and phased progress in the research and development of the company's vaccine, the company will disclose it in a timely manner. Please pay attention to the relevant information disclosed by the company for subsequent progress.
Source；https://finance.eastmoney.com/a/202509243522306220.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
